Evomela® Significantly Increases the Risk of Engraftment Syndrome in Patients with Multiple Myeloma Treated with Autologous Stem Cell Transplantation
Marshall McKenna(Rutgers, The State University of New Jersey), Michèle L. Donato(The University of Texas Health Science Center at Houston), Phyllis McKiernan(Hackensack University Medical Center), David S. Siegel(Hackensack Meridian Health), Andrew L. Pecora(Hackensack University Medical Center), David H. Vesole(Hackensack University Medical Center), Stuart L. Goldberg(Hackensack University Medical Center), Noa Biran(Hackensack University Medical Center), Scott D. Rowley(Johns Hopkins Hospital), André Goy(Hackensack University Medical Center), Themba Nyirenda(Hackensack University Medical Center)
Cited by 2
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k